A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer

Rohit Lal; James Dickson; David Cunningham; Ian Chau; Andrew R Norman; Paul J Ross; Clare Topham; Gary Middleton; Mark Hill; Jacqui Oates

doi:10.1200/JCO.2004.01.005

A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer

Rohit Lal
, James Dickson
, David Cunningham
, Ian Chau
, Andrew R Norman
, Paul J Ross
, Clare Topham
, Gary Middleton
, Mark Hill
, Jacqui Oates

Research output: Contribution to journal › Article › peer-review

38 Citations (Scopus)

Abstract

Irinotecan given until disease progression is an accepted standard treatment for advanced colorectal cancer (CRC) resistant to fluoropyrimidines. It is not known whether a predefined period of irinotecan treatment would result in similar duration of disease control. We performed a multicenter phase III trial to compare the two policies of defined-duration versus continuous irinotecan treatment.

Original language	English
Pages (from-to)	3023-31
Number of pages	9
Journal	Journal of Clinical Oncology
Volume	22
Issue number	15
DOIs	https://doi.org/10.1200/JCO.2004.01.005
Publication status	Published - 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1200/JCO.2004.01.005

Cite this

Lal, R., Dickson, J., Cunningham, D., Chau, I., Norman, A. R., Ross, P. J., Topham, C., Middleton, G., Hill, M., & Oates, J. (2004). A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. Journal of Clinical Oncology, 22(15), 3023-31. https://doi.org/10.1200/JCO.2004.01.005

@article{f000df8f5ac042d2bb2245d6ef078ab3,

title = "A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer",

abstract = "Irinotecan given until disease progression is an accepted standard treatment for advanced colorectal cancer (CRC) resistant to fluoropyrimidines. It is not known whether a predefined period of irinotecan treatment would result in similar duration of disease control. We performed a multicenter phase III trial to compare the two policies of defined-duration versus continuous irinotecan treatment.",

author = "Rohit Lal and James Dickson and David Cunningham and Ian Chau and Norman, \{Andrew R\} and Ross, \{Paul J\} and Clare Topham and Gary Middleton and Mark Hill and Jacqui Oates",

year = "2004",

doi = "10.1200/JCO.2004.01.005",

language = "English",

volume = "22",

pages = "3023--31",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15",

}

Lal, R, Dickson, J, Cunningham, D, Chau, I, Norman, AR, Ross, PJ, Topham, C, Middleton, G, Hill, M & Oates, J 2004, 'A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer', Journal of Clinical Oncology, vol. 22, no. 15, pp. 3023-31. https://doi.org/10.1200/JCO.2004.01.005

A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer. / Lal, Rohit; Dickson, James; Cunningham, David et al.
In: Journal of Clinical Oncology, Vol. 22, No. 15, 2004, p. 3023-31.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer

AU - Lal, Rohit

AU - Dickson, James

AU - Cunningham, David

AU - Chau, Ian

AU - Norman, Andrew R

AU - Ross, Paul J

AU - Topham, Clare

AU - Middleton, Gary

AU - Hill, Mark

AU - Oates, Jacqui

PY - 2004

Y1 - 2004

N2 - Irinotecan given until disease progression is an accepted standard treatment for advanced colorectal cancer (CRC) resistant to fluoropyrimidines. It is not known whether a predefined period of irinotecan treatment would result in similar duration of disease control. We performed a multicenter phase III trial to compare the two policies of defined-duration versus continuous irinotecan treatment.

AB - Irinotecan given until disease progression is an accepted standard treatment for advanced colorectal cancer (CRC) resistant to fluoropyrimidines. It is not known whether a predefined period of irinotecan treatment would result in similar duration of disease control. We performed a multicenter phase III trial to compare the two policies of defined-duration versus continuous irinotecan treatment.

U2 - 10.1200/JCO.2004.01.005

DO - 10.1200/JCO.2004.01.005

M3 - Article

C2 - 15284252

SN - 0732-183X

VL - 22

SP - 3023

EP - 3031

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

ER -

A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this